1 / 1

+ rIgG 1 13B8.2

Fig.3. A. 4 h-treatment. 10 min-treatment. 40. Non-permeabilized Jurkat T cells. + rIgG 1 13B8.2. 11%. + rIgG 1 13B8.2. Events. 10 2. 10 2. 10 1. 10 0. 10 1. 10 0. 21%. 0. Permeabilized Jurkat T cells. 40. + rIgG 1 13B8.2. + rIgG 1 13B8.2. 50%. Events. 73%. 10 2.

taro
Télécharger la présentation

+ rIgG 1 13B8.2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fig.3 A 4h-treatment 10 min-treatment 40 Non-permeabilized Jurkat T cells + rIgG1 13B8.2 11% + rIgG1 13B8.2 Events 102 102 101 100 101 100 21% 0 Permeabilized Jurkat T cells 40 + rIgG1 13B8.2 + rIgG1 13B8.2 50% Events 73% 102 101 100 0 102 101 100 Anti-ceramide antibody B 50 40 30 Ceramide-positive Jurkat T cells (%) 20 10 0 Inhibitor - - FB1 FB1 Imi Imi Myr Myr rIgG1 13B8.2 - + - + - + - +

More Related